PPAR, peroxisome proliferatoractivated receptor gamma
Regulatory guidelines from the Medicines and Healthcare products Regulatory Agency state that only people classified as clinically obese, with a Body Mass Index (BMI) of more than 30, or those who are overweight (BMI of 27-30) with at least one weight-related health condition such as high blood pressure or type 2 diabetes, will be eligible to receive the drug
The ones that are most likely to occur (vomiting and nausea) typically occur when treatment is first started and then subside quickly
Persistent nausea that impairs daily life is not, regardless of results
Specifically, we used a bolus of 2.976 g/kg body weight infusing 120 ml over 10 min (i.e., 12 ml/min), followed by a constant infusion of 0.051 g/kg body weight of 120 ml over 60 min (i.e., 2 ml/min), with 10 ml remaining in the infusion system